Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
Oral Oxymatrine Preparation for Chronic Hepatitis B: A Systematic Review of Randomized Controlled Trials
  
View Full Text  View/Add Comment  Download reader
KeyWord:oxymatrine, alkaloid, Chinese herb, hepatitis B, chronic, systematic review
Author NameAffiliationE-mail
SONG Wei-jiang, LUO Jing, WU Tong   
YAO Shu-kun Department of Gastroenterology, China-Japan Friendship Hospital, Beijing (100029), China yao_sk@163.com 
Hits: 868
Download times: 0
Abstract:
      Objective: To evaluate the efficacy and safety of oral oxymatrine preparation for the treatment of chronic hepatitis B (CHB). Methods: Randomized controlled trials (RCTs) on oral oxymatrine preparation in treating patients with CHB were retrieved until October 2013 by searching PubMed, the Cochrane Library, Embase and four Chinese databases, irrespective of language and publication status. Data extraction and data analyses were conducted according to the Cochrane standards. The risk of bias for each included trials and the quality of evidence on pre-specified outcomes were assessed. The RevMan software was used for statistical analyses. Results: Totally 52 RCTs enrolling 5,227 participants were included, of which 51 RCTs were included in meta-analyses. Oral oxymatrine preparation including oxymatrine capsule and oxymatrine tablet were associated with statistically significant effect on the clearance of hepatitis B virus (HBV) DNA, HBV surface antigen and HBV e antigen, and were beneficial to the normalization of serum alanine aminotransferase and aspartate aminotransferase. Nevertheless, the overall methodological quality and the quality of evidence in the included trials were poor. In addition, safety of oral oxymatrine preparation was not confirmed. Conclusions: Oral oxymatrine preparation showed some potential benefits for patients with CHB. However, the overall quality of evidence was limited and the safety of oral oxymatrine preparation for CHB patients was still unproven. More high quality evidence from rigorously designed RCTs is warranted to support the clinical use of oral oxymatrine reparation for patients with CHB.
Close